ADC Therapeutics Q1 Revenue $20.03M Beats Estimates, EPS -$0.21 Misses
ADC Therapeutics reported Q1 EPS of -$0.21, missing the -$0.19 estimate, while revenue of $20.03 million edged past forecasts but declined from $23.03 million a year ago. The company holds $231 million cash, a 4.09 current ratio supporting a runway into 2028, and expects LOTIS-5 and LOTIS-7 data by year-end.
1. Q1 2026 Financial Performance
ADC Therapeutics reported a Q1 EPS loss of $0.21 versus the $0.19 estimate, improving from a $0.36 loss last year. Revenue reached $20.03 million, narrowly topping the $19.99 million forecast but down from $23.03 million in Q1 2025.
2. Strong Liquidity and Runway
The company maintains a current ratio of 4.09 and holds $231 million in cash and equivalents as of March 31, 2026. These metrics, along with a negative P/E ratio of -4.19 and a debt-to-equity of -1.95, underpin a projected cash runway into 2028.
3. Pipeline Outlook and Milestones
ADC Therapeutics continues advancing its antibody-drug conjugate pipeline, with pivotal data expected from the LOTIS-5 and LOTIS-7 trials by year-end. These studies target both hematologic malignancies and solid tumors under the ZYNLONTA program and beyond.